Soleno Therapeutics (SLNO) Preferred Stock Liabilities (2016)
Historic Preferred Stock Liabilities for Soleno Therapeutics (SLNO) over the last 4 years, with Q4 2016 value amounting to $13.0.
- Soleno Therapeutics' Preferred Stock Liabilities rose 16000.0% to $13.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $13.0, marking a year-over-year increase of 16000.0%. This contributed to the annual value of $13.0 for FY2016, which is 16000.0% up from last year.
- According to the latest figures from Q4 2016, Soleno Therapeutics' Preferred Stock Liabilities is $13.0, which was up 16000.0% from $5.0 recorded in Q4 2015.
- Soleno Therapeutics' Preferred Stock Liabilities' 5-year high stood at $15.4 million during Q4 2013, with a 5-year trough of $5.0 in Q4 2015.
- In the last 4 years, Soleno Therapeutics' Preferred Stock Liabilities had a median value of $7.7 million in 2014 and averaged $7.7 million.
- Within the past 5 years, the most significant YoY rise in Soleno Therapeutics' Preferred Stock Liabilities was 16000.0% (2016), while the steepest drop was 16000.0% (2016).
- Soleno Therapeutics' Preferred Stock Liabilities (Quarter) stood at $15.4 million in 2013, then decreased by 0.0% to $15.4 million in 2014, then tumbled by 100.0% to $5.0 in 2015, then skyrocketed by 160.0% to $13.0 in 2016.
- Its Preferred Stock Liabilities stands at $13.0 for Q4 2016, versus $5.0 for Q4 2015 and $15.4 million for Q3 2014.